Vistagen Receives Notice From European Patent Office Of Intention To Grant Patent For AV-101 To Treat Neuropathic Pain
Preclinical data in four well-established preclinical models of pain associated with tissue inflammation and nerve injury demonstrate AV-101's robust effects similar to gabapentin but with a better side effect